Free and total biotherapeutic evaluation in chromatographic assays: interference from targets and immunogenicity.

Measurement of drug concentrations is critical during drug development, supporting evaluation of safety and efficacy in the context of pharmacokinetics. Protein-based therapeutics have been historically measured by immunoassay methods. Technological advances provide new opportunities to measure these biotherapeutics using previously incompatible chromatographic techniques, such as MS. These advances are breaking down the barriers between 'large-molecule' and 'small-molecule' bioanalysis, and pushing scientists outside their comfort zones. One challenge in measuring biotherapeutic concentration is potential impact from other matrix components, such as therapeutic target or antidrug antibodies. Depending on the specific assay development objective, target interference could be either desired (favoring free measurement) or undesired (favoring total measurement). Orthogonal techniques provide additional tools to meet this challenge. The goal of this review is to introduce both small- and large-molecule bioanalytical scientists to the opportunities and challenges to consider while evaluating orthogonal methods for biotherapeutic bioanalysis.

[1]  Gary Walsh,et al.  Biopharmaceuticals: recent approvals and likely directions. , 2005, Trends in biotechnology.

[2]  M. Duncan,et al.  Influence of surfactants upon protein/peptide adsorption to glass and polypropylene , 1995 .

[3]  Hendrik Neubert,et al.  Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. , 2008, Analytical chemistry.

[4]  J. Chaires,et al.  Calorimetry and thermodynamics in drug design. , 2008, Annual review of biophysics.

[5]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[6]  G. Scott,et al.  Assessment of DBS technology for the detection of therapeutic antibodies. , 2010, Bioanalysis.

[7]  Denise M O'Hara,et al.  Critical ligand binding reagent preparation/selection: When specificity depends on reagents , 2007, The AAPS Journal.

[8]  D R Mani,et al.  Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. , 2009, Clinical chemistry.

[9]  L L Needham,et al.  Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. , 1996, Clinical chemistry.

[10]  C. Horváth,et al.  Theory for electrostatic interaction chromatography of proteins. , 1991, Analytical chemistry.

[11]  Gennifer E. Merrihew,et al.  Expediting the development of targeted SRM assays: using data from shotgun proteomics to automate method development. , 2009, Journal of proteome research.

[12]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[13]  Xinping Fang,et al.  LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. , 2007, Analytical chemistry.

[14]  J. Israelachvili.  Intermolecular and surface forces , 1985 .

[15]  C. Lenz,et al.  Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. , 2009, Analytical chemistry.

[16]  A. Mire-Sluis,et al.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.

[17]  Steven P Gygi,et al.  The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. , 2005, Methods.

[18]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[19]  Darrell Ricke,et al.  Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. , 2008, Analytical chemistry.

[20]  E. Ezan,et al.  Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. , 2008, Analytical chemistry.

[21]  J. Trottier,et al.  Book Review: Mass Spectrometry: Principles and Applications. E. de Hoffman, J. Charette and W. Stroobant. Wiley, Chichester 1996. ISBN 0 471 96697 5 , 1997 .

[22]  Roberto Reverberi,et al.  Factors affecting the antigen-antibody reaction. , 2007, Blood transfusion = Trasfusione del sangue.

[23]  Roland F Staack,et al.  Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification. , 2012, Bioanalysis.

[24]  Andrew N Hoofnagle,et al.  Quantitative clinical proteomics by liquid chromatography-tandem mass spectrometry: assessing the platform. , 2010, Clinical chemistry.

[25]  J. Sailstad,et al.  Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. , 2011, Bioanalysis.

[26]  D. Brems,et al.  Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.

[27]  L. Snyder,et al.  Biochemical Samples: Proteins, Nucleic Acids, Carbohydrates, and Related Compounds , 2012 .

[28]  C P Price,et al.  The matrix effects on kinetic rate constants of antibody-antigen interactions reflect solvent viscosity. , 1998, Journal of immunological methods.

[29]  Lloyd R. Snyder,et al.  Practical HPLC Method Development: Snyder/Practical , 1997 .

[30]  D. Torney,et al.  Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. , 1989, Biophysical journal.

[31]  D. Campbell,et al.  Physical Chemical Studies of Soluble Antigen-Antibody Complexes. IV. The Effect of pH on the Reaction between Bovine Serum Albumin and its Rabbit Antibodies1 , 1955 .

[32]  Faizan Ahmad,et al.  Protein-Protein Interactions: Principles, Techniques, and their Potential Role in New Drug Development , 2011, Journal of biomolecular structure & dynamics.

[33]  Qun Zhou,et al.  Distribution of α-Galactosidase A in Normal Human Kidney and Renal Accumulation and Distribution of Recombinant α-Galactosidase A in Fabry Mice , 2007 .

[34]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[35]  H. Nygren,et al.  Kinetics of antigen-antibody reactions at solid-liquid interfaces. , 1988, Journal of immunological methods.

[36]  A. Yergey,et al.  Quantifying proteins by mass spectrometry: The selectivity of SRM is only part of the problem , 2009, Proteomics.

[37]  Hossein Salimi-Moosavi,et al.  General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. , 2012, Analytical chemistry.

[38]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[39]  E. Ezan,et al.  Quantification of small therapeutic proteins in plasma by liquid chromatography-tandem mass spectrometry: application to an elastase inhibitor EPI-hNE4. , 2006, Analytical chemistry.

[40]  M. Hearn.  [9] Reversed-phase high-performance liquid chromatography , 1984 .

[41]  A. Minton,et al.  How can biochemical reactions within cells differ from those in test tubes? , 2006, Journal of Cell Science.

[42]  A. Minton,et al.  Macromolecular crowding: biochemical, biophysical, and physiological consequences. , 1993, Annual review of biophysics and biomolecular structure.

[43]  Richard J. Simpson,et al.  Proteins and proteomics : a laboratory manual , 2003 .

[44]  Olivier Heudi,et al.  Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.

[45]  M. Quaglia,et al.  Fully traceable absolute protein quantification of somatropin that allows independent comparison of somatropin standards. , 2009, Clinical chemistry.